At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

Transposons (TEs) are genetic elements that can change their positions within genome. They cause transcriptional activation or repression by inserting into regulatory elements of related genes or by ...

The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...

A Q&A With Rajesh Gandhi, MD. GANDHI: The main reasons patients and their clinicians consider switching are to simplify treatment, reduce drug interactions, and mitigate long-term safety risks. In my ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

HIV Virus Creative artwork featuring colorized 3D prints of HIV virus particles. The virus surface (red) is covered with proteins (dark blue) that enable the virus to enter and infect human cells, and ...

Existing autoimmune drugs may prevent or reverse a serious side effect faced by patients with cancer. Immunotherapy-induced type 1 diabetes is a serious side effect faced by some patients receiving ...

Adults with HIV and obesity who switched from an antiretroviral therapy (ART) regimen with an integrase strand transfer inhibitor (INSTI) and tenofovir alafenamide to doravirine with or without ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Supreme Court on June 5 made it easier for workers to file so-called "reverse discrimination" lawsuits after siding with ...